Gainers

• AIxCrypto Hldgs (NASDAQ:AIXC) stock increased by 132.0% to $1.65 during Tuesday's regular session. The market value of their outstanding shares is at $14.3 million.
• Amylyx Pharmaceuticals (NASDAQ:AMLX) stock increased by 54.45% to $33.1. The company's market cap stands at $2.3 billion.
• China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 30.13% to $4.88. The company's market cap stands at $2.0 million.
• OSR Health (NASDAQ:OSRH) shares rose 25.52% to $0.74. The market value of their outstanding shares is at $20.7 million. As per the news, the Q2 earnings report came out 2 days ago.
• Modular Medical (NASDAQ:MODD) shares increased by 25.31% to $2.97. The company's market cap stands at $12.8 million. The company's, Q1 earnings came out 2 days ago.
• Scribe Therapeutics (NASDAQ:SCTX) shares moved upwards by 25.15% to $26.52. The company's market cap stands at $342.8 million.

Losers

• DocGo (NASDAQ:DCGO) stock decreased by 26.7% to $0.52 during Tuesday's regular session. The market value of their outstanding shares is at $70.1 million. As per the press release, Q2 earnings came out yesterday.
• ALPS Group (NASDAQ:ALPS) stock decreased by 16.93% to $0.27. The company's market cap stands at $53.2 million.
• BioVie (NASDAQ:BIVI) shares declined by 16.24% to $0.98. The market value of their outstanding shares is at $8.8 million. As per the news, the Q4 earnings report came out 3 days ago.
• Jasper Therapeutics (NASDAQ:JSPR) stock decreased by 12.61% to $0.74. The market value of their outstanding shares is at $28.0 million. As per the press release, Q2 earnings came out 2 days ago.
• NextCure (NASDAQ:NXTC) stock decreased by 12.52% to $6.75. The company's market cap stands at $35.2 million.
• Valion Bio (NASDAQ:VBIO) shares decreased by 12.11% to $0.16. The company's, Q2 earnings came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.